CA2326690A1 - The process for manufacturing topical ophthalmic preparations without systemic effects - Google Patents
The process for manufacturing topical ophthalmic preparations without systemic effects Download PDFInfo
- Publication number
- CA2326690A1 CA2326690A1 CA002326690A CA2326690A CA2326690A1 CA 2326690 A1 CA2326690 A1 CA 2326690A1 CA 002326690 A CA002326690 A CA 002326690A CA 2326690 A CA2326690 A CA 2326690A CA 2326690 A1 CA2326690 A1 CA 2326690A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- timolol
- systemic
- polymer
- topical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000699 topical effect Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 230000009885 systemic effect Effects 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims description 20
- 230000008569 process Effects 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 35
- 229920000642 polymer Polymers 0.000 claims description 19
- 229920002125 Sokalan® Polymers 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 239000004584 polyacrylic acid Substances 0.000 claims description 7
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 6
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 6
- 229940075510 carbopol 981 Drugs 0.000 claims description 6
- 229950005134 polycarbophil Drugs 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000013020 final formulation Substances 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 230000003232 mucoadhesive effect Effects 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 229920001567 vinyl ester resin Polymers 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 abstract description 24
- 229960004605 timolol Drugs 0.000 abstract description 24
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 abstract description 23
- 229960002896 clonidine Drugs 0.000 abstract description 23
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract description 4
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 abstract description 3
- 229930003347 Atropine Natural products 0.000 abstract description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract description 3
- 229960002610 apraclonidine Drugs 0.000 abstract description 3
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 abstract description 3
- 229960000396 atropine Drugs 0.000 abstract description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 abstract description 3
- 229960003679 brimonidine Drugs 0.000 abstract description 3
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 2
- 206010010904 Convulsion Diseases 0.000 abstract description 2
- 206010012735 Diarrhoea Diseases 0.000 abstract description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract description 2
- 229930182566 Gentamicin Natural products 0.000 abstract description 2
- 208000001953 Hypotension Diseases 0.000 abstract description 2
- 206010022998 Irritability Diseases 0.000 abstract description 2
- 206010028813 Nausea Diseases 0.000 abstract description 2
- 229930193140 Neomycin Natural products 0.000 abstract description 2
- 206010037660 Pyrexia Diseases 0.000 abstract description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 abstract description 2
- 206010041349 Somnolence Diseases 0.000 abstract description 2
- 208000001871 Tachycardia Diseases 0.000 abstract description 2
- 206010046555 Urinary retention Diseases 0.000 abstract description 2
- 206010047700 Vomiting Diseases 0.000 abstract description 2
- 208000006673 asthma Diseases 0.000 abstract description 2
- 229960002537 betamethasone Drugs 0.000 abstract description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 abstract description 2
- 230000036471 bradycardia Effects 0.000 abstract description 2
- 208000006218 bradycardia Diseases 0.000 abstract description 2
- 230000002612 cardiopulmonary effect Effects 0.000 abstract description 2
- 229960003405 ciprofloxacin Drugs 0.000 abstract description 2
- 230000036461 convulsion Effects 0.000 abstract description 2
- 229960003957 dexamethasone Drugs 0.000 abstract description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract description 2
- 206010013781 dry mouth Diseases 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 abstract description 2
- 229960003704 framycetin Drugs 0.000 abstract description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 abstract description 2
- 229960002518 gentamicin Drugs 0.000 abstract description 2
- 230000036543 hypotension Effects 0.000 abstract description 2
- 229960001798 loteprednol Drugs 0.000 abstract description 2
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 abstract description 2
- 230000003547 miosis Effects 0.000 abstract description 2
- 239000003604 miotic agent Substances 0.000 abstract description 2
- 230000008693 nausea Effects 0.000 abstract description 2
- 229960004927 neomycin Drugs 0.000 abstract description 2
- 208000035824 paresthesia Diseases 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 230000006794 tachycardia Effects 0.000 abstract description 2
- 230000008673 vomiting Effects 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 229960004484 carbachol Drugs 0.000 abstract 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 229940023490 ophthalmic product Drugs 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 229960004324 betaxolol Drugs 0.000 description 17
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 17
- 239000008215 water for injection Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 11
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229960002925 clonidine hydrochloride Drugs 0.000 description 8
- 229960005221 timolol maleate Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960001802 phenylephrine Drugs 0.000 description 4
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- -1 Loteprednol Ebanoate Chemical compound 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 2
- 229960000831 levobunolol Drugs 0.000 description 2
- 230000002911 mydriatic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229940048400 fucidin Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002704 metipranolol Drugs 0.000 description 1
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 210000004083 nasolacrimal duct Anatomy 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN90BO1999 IN185228B (enrdf_load_stackoverflow) | 1999-02-03 | 1999-02-03 | |
| IN90/BOM/99 | 1999-02-03 | ||
| PCT/IN2000/000008 WO2000049990A2 (en) | 1999-02-03 | 2000-02-02 | The process for manufacturing topical ophthalmic preparations without systemic effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2326690A1 true CA2326690A1 (en) | 2000-08-31 |
Family
ID=11077485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002326690A Abandoned CA2326690A1 (en) | 1999-02-03 | 2000-02-02 | The process for manufacturing topical ophthalmic preparations without systemic effects |
Country Status (11)
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011061252A2 (en) | 2009-11-18 | 2011-05-26 | Galderma Research & Development | Combination therapy for treating or preventing an inflammatory skin disorder |
| EP2388007A1 (en) | 2003-05-27 | 2011-11-23 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing rosacea |
| EP2481412A1 (en) | 2004-05-25 | 2012-08-01 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| WO2013001073A1 (en) | 2011-06-29 | 2013-01-03 | Galderma Research & Development | A new stable anesthetic composition for reducing skin reactions |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8858961B2 (en) | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| BR0109317A (pt) * | 2000-07-14 | 2003-06-17 | Allergan Inc | Composições contendo componentes agonistas alfa-2-adrenérgicos |
| AU2005220199B2 (en) * | 2000-07-14 | 2007-03-08 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| DE10132876A1 (de) * | 2001-07-06 | 2003-01-30 | Medproject Pharma Entwicklungs | Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge |
| RU2641021C2 (ru) | 2013-02-15 | 2018-01-17 | Аллерган, Инк. | Имплантат для пролонгированной доставки лекарственного средства |
| WO2014150899A1 (en) * | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Topical ophthalmic formulations for treating migraine |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| HK1248570A1 (zh) | 2015-05-29 | 2018-10-19 | 西德奈克西斯公司 | D2o稳定化的药物制剂 |
| GB202110420D0 (en) * | 2021-07-20 | 2021-09-01 | Rosemont Pharmaceuticals Ltd | Liquid pharmaceutical composition of clonidine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6056684B2 (ja) * | 1977-11-07 | 1985-12-11 | 東興薬品工業株式会社 | 点眼剤 |
| DD294174A5 (de) * | 1990-05-04 | 1991-09-26 | Sigrid Keipert | Ophthalmika mit retardwirkung und ein neues verfahren zu ihrer herstellung |
| FR2678832B1 (fr) * | 1991-07-10 | 1995-03-17 | Europhta Sa Laboratoire | Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation. |
| FR2679773A1 (fr) * | 1991-07-30 | 1993-02-05 | Merck Sharp & Dohme | Preparation ophtalmique contenant un agent osmotique acceptable antimicrobien. |
| DE19614823A1 (de) * | 1996-04-15 | 1997-10-16 | Mann Gerhard Chem Pharm Fab | Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge |
-
1999
- 1999-02-03 IN IN90BO1999 patent/IN185228B/en unknown
-
2000
- 2000-02-02 AP APAP/P/2000/001977A patent/AP2000001977A0/en unknown
- 2000-02-02 CA CA002326690A patent/CA2326690A1/en not_active Abandoned
- 2000-02-02 BR BR0004530-6A patent/BR0004530A/pt not_active Application Discontinuation
- 2000-02-02 EP EP00925571A patent/EP1139970A2/en not_active Withdrawn
- 2000-02-02 IL IL13882400A patent/IL138824A0/xx unknown
- 2000-02-02 EA EA200000918A patent/EA200000918A1/ru unknown
- 2000-02-02 WO PCT/IN2000/000008 patent/WO2000049990A2/en not_active Application Discontinuation
- 2000-02-02 AU AU44291/00A patent/AU4429100A/en not_active Abandoned
- 2000-02-02 ID IDW20002252A patent/ID28121A/id unknown
- 2000-11-01 ZA ZA200006252A patent/ZA200006252B/en unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2388007A1 (en) | 2003-05-27 | 2011-11-23 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing rosacea |
| EP2815748A1 (en) | 2003-05-27 | 2014-12-24 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing rosacea |
| EP2481412A1 (en) | 2004-05-25 | 2012-08-01 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| WO2011061252A2 (en) | 2009-11-18 | 2011-05-26 | Galderma Research & Development | Combination therapy for treating or preventing an inflammatory skin disorder |
| EP2329849A1 (en) | 2009-11-18 | 2011-06-08 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| WO2013001073A1 (en) | 2011-06-29 | 2013-01-03 | Galderma Research & Development | A new stable anesthetic composition for reducing skin reactions |
Also Published As
| Publication number | Publication date |
|---|---|
| AP2000001977A0 (en) | 2000-12-31 |
| AU4429100A (en) | 2000-09-14 |
| ID28121A (id) | 2001-05-03 |
| EA200000918A1 (ru) | 2001-10-22 |
| WO2000049990A3 (en) | 2001-07-26 |
| EP1139970A2 (en) | 2001-10-10 |
| WO2000049990A2 (en) | 2000-08-31 |
| IN185228B (enrdf_load_stackoverflow) | 2000-12-09 |
| IL138824A0 (en) | 2001-10-31 |
| BR0004530A (pt) | 2001-04-03 |
| ZA200006252B (en) | 2001-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0538313B1 (en) | Topical ophthalmic suspensions | |
| US5710182A (en) | Ophthalmic composition | |
| EP1028707B1 (en) | Sustained release ophthalmic compositions containing water soluble medicaments | |
| EP2588078B1 (fr) | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur | |
| EP2109442B1 (en) | Ophthalmic compositions containing a synergistic combination of three polymers | |
| US5795913A (en) | Ophthalmic composition | |
| CA2326690A1 (en) | The process for manufacturing topical ophthalmic preparations without systemic effects | |
| Chang et al. | Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol | |
| CN103747786A (zh) | 比马前列素和溴莫尼定的固定剂量组合 | |
| WO2011018800A2 (en) | A novel in-situ gel forming solution for ocular drug delivery | |
| US20110003816A1 (en) | Ophthalmic composition | |
| EP1189595B1 (en) | Ophthalmic compositions in form of aqueous gels | |
| Rathore et al. | Preparation and characterization of timolol maleate ocular films | |
| MXPA00009715A (en) | The process for manufacturing topical ophthalmic preparations without systemic effects | |
| EP1137407B1 (en) | Ophthalmic formulation comprising a beta blocker and carbopol | |
| JP2013129604A (ja) | 緑内障治療薬を含有する徐放性フィルム製剤 | |
| WO2024241345A1 (en) | Ophthalmic suspension composition of brinzolamide and latanoprost | |
| HK1013953B (en) | Ophthalmic composition with decreased viscosity | |
| TW200301128A (en) | Ophthalmic composition for the treatment of glaucoma, ocular hypertension, ocular ischemia and related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |